177Lu SPECT/CT Accreditation
The EARL 177Lu SPECT/CT Accreditation provides a framework for standardised evaluation and harmonisation of quantitative SPECT/CT imaging for 177Lu radiopharmaceutical therapy.
The programme has been developed in response to the rapidly expanding use of 177Lu radiopharmaceuticals, including established radioligands such as [177Lu]Lu-DOTA-TATE and [177Lu]Lu-PSMA-ligants, as well as emerging applications such as [177Lu]Lu-FAPI. Standardised post-therapy quantitative SPECT/CT is increasingly important for treatment verification, dosimetry, and clinical trials, while differences in imaging protocols can hamper comparability and scientific progress.
The accreditation is currently intended for SPECT/CT systems equipped with 3/8-inch NaI crystals. Centres using 5/8-inch NaI or CZT systems are also welcome to submit their data, contributing to the ongoing evaluation of performance across different detector technologies.
Following the successful pilot study and its final data analysis, EARL is now opening the accreditation to centres wishing to participate. Submitted results will be reviewed and re-evaluated over time as additional data and experience become available. This iterative approach will allow the accreditation to evolve with advances in technology, methodology, and clinical practice, supporting harmonisation of 177Lu SPECT/CT across the global community.
A uniformity phantom and a modified NEMA IEC Body 2018 phantom are required, as well as 177Lu activity.
Limits of Acceptability
The current EARL limits of acceptability for 177Lu SPECT/CT accreditation are provided below:
ICF: +/- 10% bias
Modified NEMA IEC phantom spheres | Upper & lower limit | |
Diameter (mm) | Volume (mL) | |
60 | 113.10 | 0.7128 – 0.9566 |
37 | 26.52 | 0.6236 – 0.8824 |
28 | 11.49 | 0.5900 – 0.8601 |
22 | 5.57 | 0.5332 – 0.7443 |
17 | 2.57 | 0.4189 – 0.6258 |
13 | 1.15 | 0.1491 – 0.3206 |
*The limits represent the current acceptance criteria for the EARL 177Lu SPECT/CT Accreditation. As this is a newly established accreditation programme, these limits will be continuously evaluated and may be revised during the first 18 months of the programme as additional accreditation data and experience are collected. Any updates will be communicated and reflected on this page.
Enrolment: centres interested in participating are invited to complete the enrolment form and join the growing network of centres contributing to the standardisation and harmonisation of quantitative 177Lu SPECT/CT. Please allow up to 10 working days for your centre to be enroled after submitting the form.
There is no fee for joining this new accreditation for 2026.
We extend our gratitude to all the centres that expressed interest and submitted data for the initial pilot study.
Join us for the EARL special symposium on Sunday 18 October 2026 to see the results from this groundbreaking study at the Annual EANM Congress in Vienna.
What our experts say on the importance of this new accreditation!
Contact us: earl@eanm.org